Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ib/II Study of CM313 (SC) in Platelet Transfusion Refractoriness
CTR20250533Phase 2Active
- Sponsor
- Keymed Biosciences
- Start
- Feb 2025
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
A Phase 2 trial of cm313 in platelet transfusion refractoriness (PTR), sponsored by Keymed Biosciences. Started Feb 2025; status: active.
02
Drugs
cm313
03
Conditions
platelet transfusion refractoriness (PTR)
Beyond the preview
Go deeper on CTR20250533.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20250533.